These asthma therapies have been directed against interleukin 4/interleukin 13, thymic stromal lymphopoietin, CRTH2 antagonists, and the IL-3/5/GM-CSF axis, and bring the possibility of improved asthma control for patients with severe asthma. This evidence concerns the gene IL4 and asthma.